Skip To Main Content

Artikelen

Sort by

Filters

Resetten
  • Therapeutische gebieden
Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Need to identify risk of developing autoimmune type 1 diabetes? Test for autoantibodies!

Anti-islet autoantibodies that target proteins associated with beta-cells serve as biomarkers of autoimmune type 1 diabetes (T1D) development.1 The number of detectable autoantibodies through screening correlates with risk of developing autoimmune T1D.2 Assays for detecting autoimmune T1D have shown high sensitivity and specificity.3,4

Wat als een voorgeschiedenis van botbreuken en pijn wijst op een zeldzame ziekte?

Wat als een voorgeschiedenis van botbreuken en pijn wijst op een zeldzame ziekte?

Klinische casus: Een 18-jarige met heuppijn en mank lopen

Exploring the Unique Characteristics of Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Exploring the Unique Characteristics of Atopic Dermatitis (AD) and Prurigo Nodularis (PN)

Explore the distinct clinical manifestations of Atopic Dermatitis (AD) and Prurigo Nodularis (PN), their impact on patients' lives, and the common thread of type 2 inflammation. Understand how these chronic skin conditions differ and intersect in this comprehensive overview.

Switching from other basal insulins to Toujeo<sup>®</sup> (Insulin Glargine)

Switching from other basal insulins to Toujeo (Insulin Glargine)

The Deliver-G study

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

The RESTORE-G Real World Evidence Study

The RESTORE-G Real World Evidence Study

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

The observational ORION study

The observational ORION study

Real-world safety and effectiveness of insulin glargine 300 U/mL in participants with type 2 diabetes who fast during Ramadan.

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?<sup>1</sup>

Glycaemic Targets and Vascular Complications in Type 2 Diabetes: What Are the Thresholds?

Summary of Zoungas S, et al. Diabetologia. 2012;55:636–643.

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

De kracht om de chaos van RSV te verminderen<sup>1-4</sup>

De kracht om de chaos van RSV te verminderen1-4

When to Initiate Basal Insulin?

When to Initiate Basal Insulin?

Practical Guidance based on the 2022 ADA/EASD Guidelines.